facebook tracking

NPPA

NPPA Revised MRP List of Non-Scheduled Anti-Cancer Drugs – Effective 9 November 2026


regulatory illustration
Importer & Manufacturer   |   Source: NPPA
Published On: 27-10-2026

Enforcement Date: 09 November, 2026
NPPA Revised MRP List of Non-Scheduled Anti-Cancer Drugs – Effective 9 November 2026

The National Pharmaceutical Pricing Authority (NPPA) has published a company-wise list of revised maximum retail prices (MRPs) for specified non-scheduled anti-cancer medicines. Based on information received from pharmaceutical companies up to 27 October 2026, the list provides old and revised MRPs across 543 brand, strength and pack-size entries.


The National Pharmaceutical Pricing Authority (NPPA) has released the revised MRP list for specified non-scheduled anti-cancer medicines covered under its trade margin rationalisation initiative. The document contains 543 company-wise entries, detailing the drug name, strength, dosage form, brand name, pack size, old MRP and revised MRP.


Key points include:

  1. The list covers formulations across several anti-cancer drug categories, including targeted therapies, hormonal therapies, immunotherapies and chemotherapy medicines.
  2. It includes products from multiple pharmaceutical companies, covering both branded and generic formulations.
  3. Revised MRPs are specified separately for individual brands, strengths, dosage forms and pack sizes.
  4. The list includes both reduced and unchanged MRPs, therefore, the extent of price revision varies across products.
  5. The revised prices are effective from 9 November 2026.
  6. The data is based on information received from companies up to 27 October 2026.

Applicable For: Importer & Manufacturer
Reference Number: Na Notification Link

Related Regulatory Updates

Contact us

Please feel free to talk to us if you have any questions. We endeavour to answer within 24 hours.